Cambridge, MA and Wilmington, DE – April 22, 2013 -- BIND Therapeutics and AstraZeneca announced today that they have entered into a strategic collaboration to develop and commercialize an AccurinTM, a targeted and programmable cancer nanomedicine from BIND's Medicinal Nanoengineering platform, based on a molecularly targeted kinase inhibitor developed and owned by AstraZeneca.

--Additional Intellectual Property Issued for T2HemoStat™ and Additional Data Presentations Planned--

LEXINGTON, Mass.--(BUSINESS WIRE)--

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced advances in its hemostasis product development program for T2HemoStat™, which rapidly detects physical changes in a blood sample such as coagulation, fibrinolysis and platelet function, from small volumes of whole blood or plasma on a single, compact instrument.

SOUTH SAN FRANCISCO, Apr 17, 2013 (GLOBE NEWSWIRE via COMTEX) -- LS9, Inc., a technology leader in the development of renewable and sustainable chemicals and fuels, today announced the expansion of its operations at the Company's Okeechobee, Florida demonstration facility with a successful customer trial. The Florida facility was initially designed, and has been used, to scale-up LS9's fermentation technology and generate large commercial samples for testing and product qualification by key partners and prospective customers.

Enables industrial CO₂ emitters to profit from applying waste streams for lucrative fuel markets

- Company Founded Based on Leading Gene Control Science and Technologies,

Co-founded by World-Leading Scientists and Top-Tier Life Sciences

Venture Capital Firms -

- Founders' Data Describing Breakthrough Discoveries Published Today in Cell -

WALTHAM, Mass., April 10, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, welcomed the announcement today that Abbott has obtained a CE Mark for the Galectin-3 assay run on the ARCHITECT immunochemistry platform.

Complete Phase 1 Results Support Advancing BIND-014 into Phase 2 Clinical Development for Multiple Solid Tumor Indications

SAN DIEGO, April 4, 2013 /PRNewswire/ -- Receptos, Inc., a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today that it has filed a registration statement on Form S-1 with the U.S.

--T2 Bio Continues to Expand Intellectual Property Portfolio Covering T2MR^® Technology and Assays--

IDH1 and IDH2 Mutant Inhibitors Reverse Differentiation Blocks in Patient-Derived Tumor Samples